Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study

被引:9
作者
Akiyama, Matthew J. [1 ]
Muller, Abbe [2 ]
Huang, Owen [1 ]
Lizcano, John [2 ]
Nyakowa, Mercy [3 ]
Riback, Lindsey [1 ]
Ross, Jonathan [1 ]
Bundi, Henry [3 ]
Kulabi, Euphrasia Shitachi [3 ]
Mwangi, Ann Muthoni [3 ]
Musyoki, Helgar [3 ]
Cherutich, Peter [3 ]
Kurth, Ann [2 ]
机构
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
[2] Yale Univ, Yale Sch Nursing, Orange, CT USA
[3] Kenya Minist Hlth, Natl AIDS & STI Control Program NASCOP, Nairobi, Kenya
基金
美国国家卫生研究院;
关键词
Hepatitis C virus (HCV); people who inject drugs (PWID); injection drug use (IDU); low; and middle-income country (LMIC); needle syringe programmes (NSP);
D O I
10.1080/17441692.2021.1896763
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Despite disproportionately high rates of Hepatitis C (HCV) among people who inject drugs (PWID) in low- and middle-income countries (LMICs), understanding of HCV-related knowledge, attitudes and perceived risk behaviours among this population remains limited. We aimed to elucidate knowledge, attitudes and experiences that could minimise transmission risk and maximise HCV treatment engagement among PWID in Kenya following the integration of HCV screening and education with needle and syringe programmes in drop-in-centres (DICs). We recruited 40 PWID with chronic HCV attending DICs in Nairobi and Coastal Kenya. Semi-structured interviews revealed a general understanding of HCV and awareness of HCV risk behaviours among participants; however, many felt limited control over their transmission risk due to factors such as 'local doctors', or individuals who perform a high volume of high-risk injections. Financial barriers, distance to clinic, poor health status and HCV-related stigma were all noted as barriers to HCV treatment. In conclusion, basic knowledge of and motivation for HCV treatment among PWID accessing DICs in Kenya was high; however, structural barriers and stigma complicate access to care. Local education programmes can address knowledge gaps, and behavioural and structural interventions can maximise the impact of HCV care in LMICs.
引用
收藏
页码:1016 / 1028
页数:13
相关论文
共 48 条
  • [1] Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study
    Akiyama, Matthew J.
    Cleland, Charles M.
    Lizcano, John A.
    Cherutich, Peter
    Kurth, Ann E.
    [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (11) : 1255 - 1263
  • [2] Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy A Randomized Controlled Trial
    Akiyama, Matthew J.
    Norton, Brianna L.
    Arnsten, Julia H.
    Agyemang, Linda
    Heo, Moonseong
    Litwin, Alain H.
    [J]. ANNALS OF INTERNAL MEDICINE, 2019, 170 (09) : 594 - +
  • [3] Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa, Yibeltal
    Hill, Peter S.
    Ulikpan, Anar
    Williams, Owain D.
    [J]. GLOBALIZATION AND HEALTH, 2017, 13
  • [4] Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study
    Barocas, Joshua A.
    Brennan, Meghan B.
    Hull, Shawnika J.
    Stokes, Scott
    Fangman, John J.
    Westergaard, Ryan P.
    [J]. HARM REDUCTION JOURNAL, 2014, 11
  • [5] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
    Blach, Sarah
    Zeuzem, Stefan
    Manns, Michael
    Altraif, Ibrahim
    Duberg, Ann-Sofi
    Muljono, David H.
    Waked, Imam
    Alavian, Seyed M.
    Lee, Mei-Hsuan
    Negro, Francesco
    Abaalkhail, Faisal
    Abdou, Ahmed
    Abdulla, Maheeba
    Abou Rached, Antoine
    Aho, Inka
    Akarca, Ulus
    Al Ghazzawi, Imad
    Al Kaabi, Saad
    Al Lawati, Faryal
    Al Namaani, Khalid
    Al Serkal, Youssif
    Al-Busafi, Said A.
    Al-Dabal, Layla
    Aleman, Soo
    Alghamdi, Abdullah S.
    Aljumah, Abdulrahman A.
    Al-Romaihi, Hamad E.
    Andersson, Monique I.
    Arendt, Vic
    Arkkila, Perttu
    Assiri, Abdullah M.
    Baatarkhuu, Oidov
    Bane, Abate
    Ben-Ari, Ziv
    Bergin, Colm
    Bessone, Fernando
    Bihl, Florian
    Bizri, Abdul R.
    Blachier, Martin
    Blasco, Antonio J.
    Mello, Carlos E. Brandao
    Bruggmann, Philip
    Brunton, Cheryl R.
    Calinas, Filipe
    Chan, Henry L. Y.
    Chaudhry, Asad
    Cheinquer, Hugo
    Chen, Chien-Jen
    Chien, Rong-Nan
    Choi, Moon Seok
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03): : 161 - 176
  • [6] Boyatzis R.E., 1998, TRANSFORMING QUALITA
  • [7] Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
    Butner, Jenna L.
    Gupta, Neil
    Fabian, Chris
    Henry, Susan
    Shi, Julia M.
    Tetrault, Jeanette M.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2017, 75 : 49 - 53
  • [8] Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents
    Calabrese, Sarah K.
    Martin, Staci
    Wolters, Pamela L.
    Toledo-Tamula, Mary A.
    Brennan, Tara L.
    Wood, Lauren V.
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2012, 24 (09): : 1092 - 1096
  • [9] Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review
    Caven, Madeleine
    Malaguti, Amy
    Robinson, Emma
    Fletcher, Emma
    Dillon, John F.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 72 : 169 - 176
  • [10] On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study
    Chikovani, Ivdity
    Ompad, Danielle C.
    Uchaneishvili, Maia
    Sulaberidze, Lela
    Sikharulidze, Ketevan
    Hagan, Holly
    Van Devanter, Nancy L.
    [J]. PLOS ONE, 2019, 14 (04):